Article

Paternity rates for men in their 30s increasing

Philadelphia--The birth rate for all U.S. men increased for fathers aged 30 to 39 years and decreased for fathers aged 20 to 29 years between 1993 and 2002. For fathers aged 40 and above, the rate remained stable, according to a new analysis of the federal National Vital Statistics Report.

Related Videos
Diverse group of doctors | © Flamingo Images - stock.adobe.com
Man talking with a doctor | Image Credit: © RFBSIP - stock.adobe.com
1 KOL is featured in this series.
1 KOL is featured in this series.
Evan Panken, MD, answers a question during a video interview
Illustration of Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
Related Content
UGN-102 data published in Journal of Urology as FDA weighs NMIBC approval
October 28th 2024

UGN-102 data published in Journal of Urology as FDA weighs NMIBC approval

Hannah Clarke
The phase 3 ENVISION trial met its primary end point by demonstrating a 79.6% complete response rate at 3 months following the first instillation of the therapy.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
FDA approves oral sulopenem for uncomplicated urinary tract infection
Published: October 25th 2024 | Updated: October 25th 2024

FDA approves oral sulopenem for uncomplicated urinary tract infection

Hannah Clarke
The approval is supported by data from the phase 3 SURE 1 and REASSURE trials.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB
October 24th 2024

Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB

Hannah Clarke
At 1 month, the mean decrease in the OAB-Q symptom severity subscale score was -31.2 in the 1-injection cohort vs -39.5 in the 10-injection cohort.
Healthy diet may lower risk of grade reclassification in patients with GG1 prostate cancer
October 24th 2024

Healthy diet may lower risk of grade reclassification in patients with GG1 prostate cancer

Hannah Clarke
Patients with higher baseline HEI and E-HEI scores were less likely to experience grade reclassification.
© 2024 MJH Life Sciences

All rights reserved.